Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 390 results for lung cancer

  1. Managed access

    Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  2. Prophylactic cranial irradiation compared with routine MRI follow-up in extensive-stage small-cell lung cancer: What is the effectiveness and cost effectiveness of prophylactic cranial irradiation compared with routine MRI follow-up in people with extensive-stage small-cell lung cancer without brain metastases?

    irradiation compared with routine MRI follow-up in extensive-stage small-cell lung cancer: What is the effectiveness and cost...

    Research recommendation
    Published
    27 April 2023

  3. What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non‑small‑cell lung cancer following multimodality treatment including surgery?

    effectiveness of immunotherapy in people with stage IIIA-N2 non‑small‑cell lung cancer following multimodality treatment including...

    Research recommendation
    Published
    13 November 2023

  4. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

    Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA449

  5. Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]

    Awaiting development Reference number: GID-TA11942 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Artificial intelligence for analysing chest CT images (MIB243)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .

    Medtech innovation briefing
    Published
    5 January 2021

  7. ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment (MIB39)

    NICE has developed a medtech innovation briefing (MIB) on ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment

    Medtech innovation briefing
    Published
    30 September 2015

  8. Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15)

    This guideline covers the risk of early death from heart disease and other smoking-related illnesses. It aims to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.

    Public health guideline
    Published
    24 September 2008
    View recommendations

    Sections for PH15

  9. Current evidence on the safety and efficacy of irreversible electroporation for treating primary lung cancer and metastases in the lung is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. In particular, studies should report the effect of the procedure on local tumour control and patient survival.

    efficacy of irreversible electroporation for treating primary lung cancer and metastases in the lung is inadequate in...

    Research recommendation
    Published
    9 June 2015

  10. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input

  11. What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell lung cancer following multimodality treatment including surgery?

    effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell lung cancer following multimodality treatment including...

    Research recommendation
    Published
    21 June 2019

  12. What is the cost effectiveness and safety of non-surgical ablation and stereotactic body radiotherapy compared to resection for people with metastatic colorectal cancer in the lung amenable to local treatment?

    radiotherapy compared to resection for people with metastatic colorectal cancer in the lung amenable to local treatment?...

    Research recommendation
    Published
    10 February 2020

  13. More research is needed on the following artificial intelligence (AI)‑derived software to analyse chest X‑rays alongside clinician review for suspected lung cancer in adults referred from primary care:

    software to analyse chest X‑rays alongside clinician review for suspected lung cancer in adults referred from primary care: Any...

    Research recommendation
    Published
    11 January 2024

  14. Photodynamic therapy for advanced bronchial carcinoma (HTG54)

    Evidence-based recommendations on photodynamic therapy for advanced bronchial carcinoma. This involves giving the patient something that makes them sensitive to light, then using special equipment to shine light onto the cancer to activate the substance and destroy some of the cancer.

    HealthTech guidance
    Published
    25 August 2004
    View recommendations

    Sections for HTG54

  15. Taletrectinib for treating ROS1-positive advanced non-small-cell lung cancer

    Awaiting development Reference number: GID-TA12467 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development